Akebia Therapeutics, Inc.

( )
AKBA PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
PFEPfizer Inc. 1.10%53.460.9%$1408.56m
JNJJohnson & Johnson 1.43%182.000.7%$1379.49m
BMYBristol-Myers Squibb Co. 0.59%77.151.0%$1213.26m
MRKMerck & Co., Inc. 1.03%94.800.7%$1161.73m
ABBVAbbVie, Inc. 0.81%149.231.9%$1105.06m
LLYEli Lilly & Co. 1.23%306.321.1%$918.69m
AZNAstraZeneca Plc 0.36%66.651.0%$506.93m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. -0.18%142.750.0%$479.99m
VERUVeru, Inc. -13.53%12.210.0%$284.01m
NVSNovartis AG 1.35%91.930.2%$267.50m
GSKGlaxoSmithKline Plc 0.57%45.010.2%$252.72m
HZNPHorizon Therapeutics Plc 0.74%88.035.4%$192.26m
NVONovo Nordisk A/S 0.14%108.000.1%$183.12m
SGENSeagen Inc. -4.21%133.475.7%$176.88m
VTRSViatris, Inc. -0.86%11.530.0%$163.21m

Company Profile

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.